Angiotech announces acquisition of Afmedica, Inc.
The Afmedica transaction strengthens Angiotech's market leadership with respect to its Vascular Wrap(TM) product development program, where Angiotech is currently conducting human clinical studies with its paclitaxel-eluting Vascular Wrap(TM) product candidate. The transaction enables Angiotech to potentially expand its research platform with rapamycin in perivascular and other selected disease indications. Terms of the transaction were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.